Amylyx Pharmaceuticals, Inc. AMLX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $229.14M+283% | $226.65M+193% | $225.18M+213% | $58.09M-22.6% | $59.76M-65.0% | ||
| $50.63M-64.9% | $90.33M-8.9% | $118.81M-26.9% | $122.74M-47.7% | $144.3M-28.8% | ||
| $285.02M+31.9% | $323.67M+70.9% | $353.38M+44.1% | $186.89M-42.8% | $216.14M-47.4% | ||
| $212K-74.0% | $310K-67.7% | $399K-68.1% | $445K-69.8% | $816K-66.8% | ||
| $293.6M+33.7% | $332.65M+71.8% | $362.74M+44.7% | $194.6M-41.4% | $219.68M-47.4% | ||
| $15.68M+10.5% | $16.96M-45.0% | $16.38M-67.2% | $12.53M-77.2% | $14.19M-81.0% | ||
| $15.97M-11.0% | $22.69M-20.1% | $25.79M-52.2% | $21.42M-69.4% | $17.93M-80.4% | ||
| $20.44M+12.0% | $27.39M-5.1% | $30.75M-43.6% | $26.72M-62.3% | $18.26M-80.4% | ||
| $11K+22.2% | $11K+57.1% | $11K+57.1% | $9K+28.6% | $9K+28.6% | ||
| -$792.71M-23.4% | -$751.43M-23.9% | -$718.43M-26.2% | -$684.04M-37.8% | -$642.6M-51.6% | ||
| $273.16M+35.6% | $305.26M+85.3% | $332M+69.2% | $167.88M-35.8% | $201.42M-37.9% | ||
| $293.6M+33.7% | $332.65M+71.8% | $362.74M+44.7% | $194.6M-41.4% | $219.68M-47.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Amylyx Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 17.85 — current assets exceed current liabilities.
- Where does Amylyx Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.